Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

PSTX

Poseida Therapeutics (PSTX)

Poseida Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PSTX
DateHeureSourceTitreSymboleSociété
03/06/202422h05PR Newswire (US)Poseida Therapeutics Announces Virtual 2024 Annual Meeting of StockholdersNASDAQ:PSTXPoseida Therapeutics Inc
14/05/202422h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTXPoseida Therapeutics Inc
14/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
14/05/202422h05PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024NASDAQ:PSTXPoseida Therapeutics Inc
09/05/202415h00PR Newswire (US)Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
06/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PSTXPoseida Therapeutics Inc
02/05/202403h30PR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
01/05/202421h25AllPennyStocks.comBiotech Soars on Research Collaboration And License Agreement ReleaseNASDAQ:PSTXPoseida Therapeutics Inc
18/04/202414h00PR Newswire (US)Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
17/04/202415h00PR Newswire (US)Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusNASDAQ:PSTXPoseida Therapeutics Inc
08/04/202418h00PR Newswire (US)Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
01/04/202422h05PR Newswire (US)Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSTXPoseida Therapeutics Inc
25/03/202421h05PR Newswire (US)Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerNASDAQ:PSTXPoseida Therapeutics Inc
19/03/202421h05PR Newswire (US)Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:PSTXPoseida Therapeutics Inc
13/03/202421h05PR Newswire (US)Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
07/03/202422h07PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:PSTXPoseida Therapeutics Inc
04/03/202423h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
08/02/202422h10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PSTXPoseida Therapeutics Inc
04/01/202414h00PR Newswire (US)Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key MilestonesNASDAQ:PSTXPoseida Therapeutics Inc
11/12/202316h31Dow Jones NewsPoseida Therapeutics Shares Climb on Positive Data for Blood Cancer TreatmentNASDAQ:PSTXPoseida Therapeutics Inc
10/12/202318h00PR Newswire (US)Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
09/11/202322h05PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023NASDAQ:PSTXPoseida Therapeutics Inc
07/11/202314h00PR Newswire (US)Poseida Therapeutics to Present at Two Upcoming Investor ConferencesNASDAQ:PSTXPoseida Therapeutics Inc
02/11/202314h01PR Newswire (US)Poseida Therapeutics to Present at the 65th ASH Annual Meeting and ExpositionNASDAQ:PSTXPoseida Therapeutics Inc
09/10/202322h30PR Newswire (US)Poseida Therapeutics Announces Leadership TransitionNASDAQ:PSTXPoseida Therapeutics Inc
14/08/202322h41Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:PSTXPoseida Therapeutics Inc
11/08/202322h48Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:PSTXPoseida Therapeutics Inc
08/08/202322h05PR Newswire (US)Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023NASDAQ:PSTXPoseida Therapeutics Inc
07/08/202316h41Dow Jones NewsPoseida Therapeutics Shares Leap on Astellas InvestmentsNASDAQ:PSTXPoseida Therapeutics Inc
07/08/202315h58Dow Jones NewsPoseida Therapeutics in $50 Million Investment Deal With AstellasNASDAQ:PSTXPoseida Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PSTX

Dernières Valeurs Consultées

Delayed Upgrade Clock